Abstract
Introduction

4
Antimicrobial resistance (AMR) is imposing an alarming threat to the global public health. Of 69 particular challenging in clinics are those "ESKAPE" pathogens which constitute the major 70 sources of nosocomial infections and are extraordinary to engender resistance, i.e.
71
Enterococcus spp., Staphylococcus aureus, Klebsiella spp., Acinetobacter baumannii, 72 Pseudomonas aeruginosa, and Enterobacter spp.. Owing to its intrinsic resistance to a variety 
94
Antagonistic interplay of different RND efflux pumps was also reported, especially in the nfxC 95 type MDR P. aeruginosa isolates in which over-production of the MexEF-OprN pump is often 96 concomitant with an impairment of the MexAB-OprM pump in the strain, resulting in a high 97 resistance to quinolones but a hyper-susceptibility to β-lactams [16, 17] . Compounding the 98 complexity of the resistant mutation networks is the effect of genetic background of resistant 99 strains and epistasis among different resistant mutations which are increasingly recognized to 100 play important roles in resistance development and affect the effectiveness of antibiotic 101 chemotherapies [18] [19] [20] . Hence, it is necessary to identify the key resistant determinants and 102 their collateral effects in the native genetic background of clinical MDR strains. Yet, these 103 molecular characterizations are often hindered by the lack of efficient and readily applicable 104 genomic editing tools in these "non-model" strains.
105
In addition to be a prototypical MDR pathogen, P. aeruginosa is an important model system 106 for understating CRISPR-Cas functions, especially the type I CRISPR-Cas system.
107
Phylogenetic analysis revealed that CRISPR-Cas systems are widely distributed in global
108
AMR P. aeruginosa isolates with more than 90% belonging to the I-E or I-F subtypes [21] .
109
Owing to its built-in genome targeting activity and reprogrammable feature, in recent years, causing over-production of three multidrug efflux pumps MexAB, MexEF, and MexGHI (S1 126   Table) . Genome sequencing reveals that PA154197 contains a native type I-F CRISPR-Cas 127 locus. These together renders PA154197 a paradigm to explore the harnessing of a native type 128 I-F CRISPR-Cas system for genome editing in a clinical MDR P. aeruginosa strain and 129 exploiting the system for AMR characterization in its native genetic background.
130
In this study, we report the successful development of a single plasmid-mediated, one-step, 
Results
145
PA154197 contains a functional type I-F CRISPR-Cas system.
146
Analysing the genome sequence of PA154197 reveals the presence of the signature cas8f and 147 cas6f genes and the unique cas2-cas3 fusion in its CRISPR-Cas loci, suggesting that the system 148 belongs to the subtype I-F ( Fig 1A) [29]. The cas operon of the system is found to be To harness the native CRISPR-Cas for genome editing, it is necessary to first examine its 155 endogenous genome targeting activity. We select mexB as the target gene for this purpose, of the lux operon in frame in pAY5233 such that Ptat simultaneously drives the expression of 168 both the CRISPR element and the lux operon which assists the transformant screening (Fig 1B) .
169
When the targeting plasmid pAY5233 and the control plasmid pAY5211 (which contains all 170 the elements described above except the mini-CRISPR fragment) were introduced into 171 PA154197 cells, a dramatic decrease of the transformants recovery was observed comparing 172 to the non-targeting control (Fig 1C) , implying the occurrence of the detrimental chromosome Harnessing the native type I-F CRISPR-Cas system to delete the resistance gene mexB.
177
To exploit the system for gene deletion (ΔmexB as an example), we then assemble a 1-kb donor 178 sequence consisting of the 500-bp upstream and 500-bp downstream of mexB for homologous 179 recombination, and insert it into pAY5233 to yield pAY5235, termed as the editing plasmid
180
( Fig 1D) . The number of transformants of pAY5235 is significantly increased (by more than 181 10-fold) compared to pAY5233 (Fig 1C) , suggesting the occurrence of homologous 182 recombination by provision of the donor sequence. We randomly selected eight luminescence 183 positive colonies for validation and found four colonies showed the desired, scarless and 184 precise deletion of mexB in the chromosome (Fig 1E and 1F ). These results demonstrate the 185 success of genome editing by exploitation of the native type I-F CRISPR-Cas system in the 186 clinical MDR isolate PA154197 by one-step introduction of a single editing plasmid.
187
The success rate of 4/8 seemed moderate. However, we speculate that it was due to the 188 unusually large size (3141 bp) of mexB rather than the efficiency of the editing technique, as 189 subsequent attempts to delete shorter fragments, i.e. 50-bp, 500-bp, or 1000-bp within mexB To examine the applicability of the technique in other type I-F CRISPR-Cas containing P. antimicrobial agents tested (Fig 2 and S2 Table) . Further deletion of mexH in the ΔmexB
238
ΔmexF strain yields no MIC change either (data not shown), suggesting that it does not 239 contribute to the antibiotic resistance in PA154197. A G226T point mutation in mexR is responsible for the mexAB-oprM over-expression.
242
Over-expression of efflux genes is often caused by mutations in their transcription regulators.
243
Comparative genomic analysis revealed a single nucleotide substitution G226T (corresponding 244 to introducing a stop codon following E76) in PA154197 mexR compared to PAO1 (S6A Fig). 
245
Mutations or pre-mature termination of the MexR often leads to over-production of the 246 MexAB-OprM pump (Fig 3A) OprM substrates (Fig 2 and S4 Fig) . To overcome this limitation, we devise a two-step Insert-Delete (In-Del) strategy to edit this 270 inefficiently targeted site (Fig 4A) . The approach bypasses the poorly targeted PAM- sequence (Fig 4A) . The success rate for the first and second round editing for 8-bp insertion in 280 mexT is found to be 8/8 and 5/8 (Fig 4B and 4C ). This In-Del strategy presumably allows any 281 type of non-lethal genetic manipulations regardless of PAM limitation.
282
The resulting mutant is designated as mexT PAO1 . As expected, both transcription of mexEF and 283 the MICs of LVX and CIP in the mexT PAO1 cells is reduced comparing with the WT PA154197
284
( Fig 3C, Fig 2, S2 PA154197. Consistent with the previous report of the nfxC type resistant mutation, the reverse 287 mutation mexT PAO1 also leads to a 3-fold higher transcription of oprD than the PA154197 parent 288 (Fig 3C) , which encodes a porin protein facilitating the diffusion of carbapenems antibiotics
289
(especially IPM), and an increased susceptibility to IPM in PA154197 (Fig 2 and S4 Fig) . Table) , However, reverse mutation in this gene does not reveal any susceptibility changes (S2 295   Table) , suggesting this mutation does not contribute to the antibiotic resistance development in ΔmexB or ΔmexF but not to the susceptible level of PAO1 (Fig 2 and S2 Table) . MICs in the WT PA154197 relative to isogenic mexR PAO1 cells which reflects the Table) . The observed FQ resistance by MexAB-
359
OprM is also contributed by its over-production (S3 Table) . Combining these, a rather complete 360 substrates profile of the two efflux pumps with relative expel efficiencies in the genetic 361 background of the MDR strain PA154197 is mapped (Fig 5) . This information not only Lacking of collateral sensitivity in PA154197. polymyxins with the WT which contains all three key resistant determinants (S2 Table) . 
409
In comparison with a recently reported heterologous Cas9-based genome editing method which 410 requires successive transformation of two editing plasmids [35] , and the conventional two-step 411 allelic exchange method [58] which takes more than two weeks to construct a mutant with an 412 undesirable FLP site permanently remained in the edited site, our method using a single 413 plasmid to achieve editing in one-step represents a more efficient and clean genome editing 414 technique which can be completed within one week, i.e. 3-4 days for constructing the editing is not only due to its direct expelling structurally diverse antibiotics but also the capability of 436 driving the acquisition of additional, specific resistance mechanisms by lowering intracellular 437 antibiotic concentration and promoting mutation accumulation [14, 59] . 
Material and methods
461
Bacterial strains, culture conditions.
462
All the bacterial strains used and constructed in this study are listed in S3 Plasmid construction.
469
All the plasmids constructed and used in this study are listed in S4 
